Eton Pharmaceuticals, Inc. (ETON) stock
Close on Nov 12, 2026Market cap $1.76BP/E 40.4Yield –
Eton Pharmaceuticals, Inc. grew revenue 100.6% to $141.06M over the twelve months to Sep 30, 2026. Free cash flow was $38.22M, up 81.9% from a year earlier. At the latest close the market valued the company at $1.76B, 40.4 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $1.76B
- P/E ratio
- 40.4
- Price to sales
- 12.45
- Price to book
- 20.21
- Dividend yield
- –
- Free cash flow yield
- 2.18%
Fundamentals
- Revenue
- $141.06M
- Net income
- $49.86M
- EPS, diluted
- $1.52
- Free cash flow
- $38.22M
- Book value per share
- $2.61
- Diluted shares
- 33M
Trading
- Next earnings
- Mar 18, 2027 (estimated, after the close)
- Previous close
- $68.40
- Open
- $68.38
- Day's range
- $61.36 – $69.05
- Volume
- 1,017,322
- Average volume (20 days)
- 589,512
- Index membership
- Russell 2000 (since Jun 2025), Russell 3000 (since Aug 2025)
- Beta (5 years)
- 0.87
- 52-week range
- $14.27 – $70.64
- RSI (14 days)
- 58.8
- Volatility (1 year)
- 75.0%
- Relative volume
- 1.73×
- WACC
- 9.2%
On 2 of our idea lists: Institutions accumulating, New highs on volume
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2018, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | ETON | S&P 500 | Difference | ETON per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +11.2% | -2.7% | +13.9 pts | ||
| 3 months | +47.8% | -1.7% | +49.5 pts | ||
| Year to date | +263.4% | +11.9% | +251.5 pts | ||
| 1 year | +251.9% | +12.0% | +240.0 pts | ||
| 3 years | +1500.3% | +78.2% | +1422.1 pts | +152.0% | +21.2% |
| 5 years | +1124.1% | +73.2% | +1050.9 pts | +65.0% | +11.6% |
Nine years at a glance
Fiscal years 2017 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Eton Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- News
- News
- News
- Results
- News
About Eton Pharmaceuticals
Pharmaceutical Preparations
Eton Pharmaceuticals is a pharmaceutical company that develops and commercializes treatments for rare diseases. The company operates primarily in the endocrinology and metabolic disease segments. Its commercial portfolio comprises eight approved therapies, including Increlex, Alkindi Sprinkle, Khindivi, Galzin, and PKU Golike, as well as generic formulations of carglumic acid, betaine anhydrous, and nitisinone. These medications address conditions such as adrenocortical insufficiency, growth factor deficiency, Wilson disease, and genetic metabolic disorders. The company's end consumers are rare disease patients, often children, and it distributes its therapies through specialty pharmacies to healthcare providers and patients.
Company profile, executives and historyEton Pharmaceuticals stock: common questions
What is Eton Pharmaceuticals's stock price?
ETON closed at $61.45 on Nov 12, 2026, down 10.16% on the day. Over the past 52 weeks it traded between $14.27 and $70.64.
What is Eton Pharmaceuticals's market cap?
Eton Pharmaceuticals was worth $1.76B at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is ETON's P/E ratio?
ETON trades at 40.4 times earnings, based on diluted earnings per share of $1.52 over the twelve months to Sep 30, 2026.
How much revenue does Eton Pharmaceuticals make?
Eton Pharmaceuticals reported revenue of $141.06M for the twelve months to Sep 30, 2026, up 100.6% from a year earlier.
Does Eton Pharmaceuticals pay a dividend?
No. Eton Pharmaceuticals has not paid a cash dividend over the last twelve months.
When does Eton Pharmaceuticals report earnings next?
Eton Pharmaceuticals is expected to report Q4 FY2026 results on Mar 18, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has ETON stock performed over the past year?
Including dividends, ETON returned +251.9% over the past year, against +12.0% for the S&P 500.
How many ETON shares are sold short?
2M shares were sold short at the latest FINRA report, 7.36% of the float, or 5.4 days of average trading volume.
Who are Eton Pharmaceuticals's competitors?
Companies most similar to Eton Pharmaceuticals by business, industry and size include ZVRA, AGIO, XERS, RYTM, AMLX.
See a number that looks wrong?